BroadOak Partners advised Aalto Bio Reagents on the sale of the company to Biosynth Carbosynth, a KKR and Ampersand portfolio company. The full press release is below. Addition of Aalto Bio Reagents expands Biosynth Carbosynth’s offer to its clinical diagnostics customers. Staad, 25 May 2022 - Biosynth Carbosynth...
BroadOak’s Q1 Quarterly Review analyzes market trends and M&A transactions across life science tools, diagnostics, and services sectors. Read our full Quarterly Review for more information.Download the full 1Q 2022 BroadOak M&A Newsletter....
BroadOak is pleased to announce its investment in Biolog, a leading provider of cell-based microbial identification and phenotypic profiling technologies. Operating Partner Robert Wicke will serve as CEO of Biolog. Bill Snider and Robert Wicke will also serve on the company's Board of Directors. The full...
BroadOak portfolio company Reaction Biology Corporation was acquired by Cobepa. Reaction Biology is a leading contract research organization (CRO) that provides drug discovery services to over 1,800 biopharmaceutical customers worldwide. Reaction's capabilities include functional biochemical assays, compound screening, a wide range of mechanistic and biophysical studies,...
BroadOak increased its investment in Genomenon, a company that organizes the world's genomic data. The full press release is below. Genomenon Raises $20M Series B Financing, Launching a New Era in AI-Powered Genomic Data Financing led by Beringea and Spring Mountain Capital to fuel continued growth in pharmaceutical...
BroadOak’s Q4 Quarterly Review analyzes market trends and M&A deals across life sciences tools, diagnostics, and services sectors. Read our full Quarterly Review for more information. Download the full 4Q 2021 BroadOak M&A Newsletter....
Rockland Immunochemicals, Inc. acquired antibodies-online in a transaction financed by BroadOak Capital Partners. Bill Snider, Partner at BroadOak Capital Partners commented: "We are delighted to extend our long-term partnership with Rockland to include financing that supports its acquisition of antibodies-online; a former BroadOak portfolio company. Rockland...
BroadOak Partners advised KCAS, a Vitruvian Partners portfolio company, on the acquisition of FlowMetric, LLC. FlowMetric is a leading provider of flow cytometry and cellular assay R&D services to biotech, pharmaceutical and cell and gene therapy industries. The full press release is below. KCAS Bioanalytical and Biomarker...
BroadOak Capital Partners advised JMI Laboratories (“JMI”) on the sale of the company to Element Materials Technology (“Element”). JMI is a leading provider of antimicrobial drug development, molecular testing, clinical trial support, and surveillance services to biotech and pharmaceutical companies. The full press release is below. Element...
BroadOak Capital Partners provided a senior term loan to refinance debt held by Interpace’s private equity stockholders, Ampersand Capital and 1315 Capital. Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic...
Stay connected
Partner with BroadOak